Neuralgia Treatment Market 2025-2029: Unveiling Growth Developments with the Latest Updates

 Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the neuralgia treatment industry.

 

 How Fast Is The Neuralgia Treatment Market Growing Towards 2025?
 The neuralgia treatment market size has grown strongly in recent years. It will grow from $2.3 billion in 2024 to $2.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of neuralgia, neuropathic pain awareness, rise in chronic pain conditions, presence of high disposable income, government initiatives.
 
 The neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to aging population, emerging therapies, increasing incidences of diabetes, high healthcare expenditure. Major trends in the forecast period include advancements in pain management, innovative products, digital health integration, development of new drug delivery systems.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=12921&type=smp
 
 Neuralgia Treatment Market Drivers And Opportunities
 The rising prevalence of chronic diseases, such as diabetes, is expected to propel the growth of the neuralgia treatment market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Diabetes is a long-term metabolic condition characterized by high blood glucose, also called blood sugar. Neuralgia treatment can treat diabetic neuropathy, the nerve damage that can occur in people with diabetes. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally.Therefore, the rising prevalence of chronic diseases, such as diabetes, is driving the growth of the neuralgia treatment market. 
 
 How Is The Neuralgia Treatment Market Segmented?
 The neuralgia treatmentmarket covered in this report is segmented — 
 
 1) By Treatment: Drug Based; Surgeries
 2) By Indication: Diabetic Neuropathy; Intercostal Neuralgia; Occipital Neuralgia; Peripheral Neuralgia; Postherpetic Neuralgia
 3) By Distribution channels: Drug Stores; Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
 4) By End-Use: Hospitals And Clinics; Ambulatory Surgery Centers; Other End-Users
 
 Subsegments:
 1) By Drug Based: Anticonvulsants; Antidepressants; Opioids; Topical Treatments; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
 2) By Surgeries: Nerve Block Procedures; Decompression Surgery; Neurectomy; Spinal Cord Stimulation
 
 What Are The Future Trends Of The Neuralgia Treatment Market?
 Major companies operating in the neuralgia treatment market are focused on developing innovative products and solutions to sustain their position in the market. For instance, in April 2023, in India, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, the world’s first non-live and recombinant subunit vaccine. This vaccine is designed to prevent shingles and post-herpetic neuralgia in adults aged 50 years and older and is administered intramuscularly in two doses. Shingrix combines the antigen glycoprotein E with the adjuvant system AS01B to produce a potent and long-lasting immunological response that can help counteract the immune system’s deterioration with age. Clinical trials have shown that it is 97% effective in preventing shingles in adults. It also effectively prevents post-herpetic neuralgia, a painful complication of shingles.
 
 Major Companies Operating In The Neuralgia Treatment Market Are:
 Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Horizon Therapeutics, Purdue Pharma, Dr. Reddy’s Laboratories, Cipla Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals, Tonix Pharmaceuticals.
 
 View the full neuralgia treatment market report here:
 https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
 
 Regional Analysis: Opportunities And Challenges In The Neuralgia Treatment Market
 North America was the largest region in the neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuralgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company